Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab in Recurrent dMMR Endometrial Cancer
NCT04906382Phase 1Terminated
- Start
- Jul 2021
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tislelizumab in endometrial cancer (EC). Primary endpoints: T-cell receptor (TCR) profiles up to 24 months, T-cell receptor (TCR) clonality up to 24 months and 1 more. Started Jul 2021; status: terminated.
02
Drugs
tislelizumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04906382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04906382.